ROR1 Antibodies with Optimized CDR Sequences for High Affinity Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for antigen-binding proteins that target ROR1 with high affinity and inhibitory activity, particularly for use in cancer therapy, as ROR1 is expressed in various cancers and contributes to tumor progression and metastasis.
Innovation Solution
Development of novel antibodies and antigen-binding fragments that specifically bind to the extracellular domain of ROR1, including monoclonal and bispecific antibodies, such as bispecific T-cell engagers (BiTEs), with defined light and heavy chain variable regions and linkers, to mediate killing of effector cells against cancer cells expressing ROR1.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibody development methods are used, then general binding activity may be achieved, but high affinity and inhibitory activity against ROR1 cannot be obtained
Solution Approach 1:
The patent applies preliminary action by pre-defining the CDR sequences based on known high-affinity binding patterns to ROR1 extracellular domain. The antibody variable regions are designed with specific CDR sequences (LCDR1: EVQLVQSGAE, LCDR2: RASQSVSSYLA, LCDR3: DASNRAT; HCDR1: GYTFTYR, HCDR2: TPFNGN, HCDR3: SGPRGDYVLDY) that have been predetermined to achieve high affinity binding, eliminating the need for extensive screening and development processes.
Solution Approach 2:
The patent applies parameter changes by optimizing the amino acid sequences of the CDR regions to achieve specific binding affinity parameters. The variable regions are engineered with precise sequence compositions and lengths (e.g., VL with 110 amino acids, VH with 118 amino acids) and specific CDR lengths (e.g., LCDR1: 11aa, HCDR1: 7aa) to maximize binding affinity while maintaining stability and specificity for ROR1.
2Productivity
If antibodies are designed to bind ROR1 with high affinity, then tumor cell killing activity is improved, but antibody structural complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the antibody into distinct functional modules: variable regions (VL and VH) with specifically designed CDR sequences for ROR1 binding, constant regions for effector cell engagement, and defined linker regions. The CDR segments (LCDR1-3 and HCDR1-3) are independently optimized and assembled into the complete variable regions, allowing modular design and simplifying the overall structural complexity while maintaining high killing efficiency.
Solution Approach 2:
The patent applies local quality by concentrating the complexity and specificity requirements only in the CDR regions that directly contact ROR1, while keeping the constant regions and linkers relatively simple and well-defined. The specific amino acid compositions and lengths of individual CDRs (e.g., LCDR2 with 9 amino acids, HCDR3 with 13 amino acids) are locally optimized for maximum binding affinity without complicating the entire antibody structure.
Data Source
AI summary
Disclosed herein are monoclonal antibodies against ROR1, bispecific antibodies against ROR1 and CD3, nucleic acids comprising the antibodies, vectors comprising the nucleic acids, and host cell comprising the nucleic acids or the vectors. Also disclosed are pharmaceutical compositions and antibody-drug conjugates comprising the antibodies, and therapeutic methods for using the antibodies.